サマリー

ナノ粒子薬物送達システムは、治療薬の標的送達および制御放出のためにナノ粒子を使用する工学的技術である。現代のドラッグデリバリーシステムは、副作用を最小限に抑え、投与量と投与回数の両方を減らす必要があります。近年、ナノ粒子は効果的なドラッグデリバリーへの応用が期待され、注目を集めています。

市場分析と洞察。リポソームおよびリピッドベースのナノ粒子医薬品の世界市場
リポソームおよび脂質ベースのナノ粒子医薬品の世界市場規模は、2020年のXX百万米ドルから2021-2027年の間にXX％のCAGRで推移し、2027年にはXX百万米ドルに達すると予測されています。
本レポートは、業界標準の正確な分析と高いデータの整合性により、世界のリポソームおよび脂質ベースのナノ粒子医薬品市場で利用可能な主要な機会を明らかにし、プレイヤーが市場での確固たる地位を獲得するのに役立つ見事な試みを行っています。本レポートの購入者は、検証済みで信頼性の高い市場予測にアクセスすることができます。その中には、収益面でのLiposomal and Lipid-based Nanoparticle Drug世界市場の全体的なサイズに関する予測も含まれます。
本レポートは、プレイヤーが競合他社に対して優位に立ち、Liposomal and Lipid-based Nanoparticle Drugの世界市場で永続的な成功を収めるための有効なツールであることを証明しています。本レポートに掲載されているすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、リポソームおよび脂質ベースのナノ粒子医薬品の世界市場を詳細に調査するために、独自の業界最高水準の調査・分析アプローチを採用しました。

世界のリポソームおよび脂質ベースのナノ粒子医薬品のスコープと市場規模
Liposomal and Lipid-based Nanoparticle Drug市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界のLiposomal and Lipid-based Nanoparticle Drug市場のプレーヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年の期間で、タイプ別とアプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
リポソーム医薬品
脂質ナノ粒子 医薬品

用途別セグメント
病院
小売薬局
その他

地域別
北アメリカ
アメリカ
カナダ
ヨーロッパ
ドイツ
フランス
U.K.
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
ジョンソン・エンド・ジョンソン
サン・ファーマシューティカル
CSPC
Kinyond
Teva
復旦-張江
Zydus Cadila
TTYバイオファーマ
パキラ
Luye Pharma
Leadiant Biosciences
イプセン
Sayre Therapeutics
ジャズ
アルナイラム
バウシュ・ヘルス
アクロテック・バイオファーマ
武田薬品
チエジ・ファルマチェウティチ
ギリアド・サイエンシズ

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
1.3 Market by Application
1.3.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Perspective (2016-2027)
2.2 Liposomal and Lipid-based Nanoparticle Drug Growth Trends by Regions
2.2.1 Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Liposomal and Lipid-based Nanoparticle Drug Historic Market Share by Regions (2016-2021)
2.2.3 Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Regions (2022-2027)
2.3 Liposomal and Lipid-based Nanoparticle Drug Industry Dynamic
2.3.1 Liposomal and Lipid-based Nanoparticle Drug Market Trends
2.3.2 Liposomal and Lipid-based Nanoparticle Drug Market Drivers
2.3.3 Liposomal and Lipid-based Nanoparticle Drug Market Challenges
2.3.4 Liposomal and Lipid-based Nanoparticle Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue
3.1.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (2016-2021)
3.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2016-2021)
3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Liposomal and Lipid-based Nanoparticle Drug Revenue
3.4 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio
3.4.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2020
3.5 Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Area Served
3.6 Key Players Liposomal and Lipid-based Nanoparticle Drug Product Solution and Service
3.7 Date of Enter into Liposomal and Lipid-based Nanoparticle Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Type
4.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Type (2016-2021)
4.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2022-2027)

5 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Application
5.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Application (2016-2021)
5.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
6.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
6.2.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
6.2.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
6.2.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
6.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
6.3.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
6.3.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
6.3.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
6.4 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
6.4.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
6.4.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
7.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
7.2.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
7.2.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
7.2.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
7.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
7.3.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
7.3.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
7.3.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
7.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
7.4.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
7.4.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
8.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
8.2.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
8.3.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region
8.4.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
9.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
9.2.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
9.2.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
9.2.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
9.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
9.3.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
9.3.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
9.3.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
9.4 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
9.4.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
9.4.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
10.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
10.2.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
10.3.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
10.4.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Details
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Introduction
11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Details
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Introduction
11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Details
11.3.2 CSPC Business Overview
11.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Introduction
11.3.4 CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Details
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Introduction
11.4.4 Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Details
11.5.2 Teva Business Overview
11.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Introduction
11.5.4 Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Details
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Introduction
11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Details
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Introduction
11.7.4 Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Details
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
11.8.4 TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Details
11.9.2 Pacira Business Overview
11.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Introduction
11.9.4 Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Details
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Introduction
11.10.4 Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Details
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Introduction
11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Details
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Introduction
11.12.4 Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Details
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Introduction
11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Details
11.14.2 Jazz Business Overview
11.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Introduction
11.14.4 Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Details
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Introduction
11.15.4 Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Details
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Introduction
11.16.4 Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Details
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Introduction
11.18.4 Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.18.5 Takeda Recent Development
11.18 Chiesi Farmaceutici
.1 Chiesi Farmaceutici Company Details
.2 Chiesi Farmaceutici Business Overview
.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Introduction
.4 Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Details
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Introduction
11.20.4 Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
11.20.5 Gilead Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details